Modality
siRNA
MOA
EZH2i
Target
C5
Pathway
Tau
DLBCLAsthma
Development Pipeline
Preclinical
~Jun 2011
→ ~Sep 2012
Phase 1
~Dec 2012
→ ~Mar 2014
Phase 2
~Jun 2014
→ ~Sep 2015
Phase 3
~Dec 2015
→ ~Mar 2017
NDA/BLA
Jun 2017
→ Jun 2029
NDA/BLACurrent
NCT03534574
1,076 pts·DLBCL
2019-07→2028-11·Terminated
NCT05465552
809 pts·DLBCL
2017-06→2029-06·Active
1,885 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-11-272.7y awayPh3 Readout· DLBCL
2029-06-183.2y awayPh3 Readout· DLBCL
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Active
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-11-27 · 2.7y away
DLBCL
Ph3 Readout
2029-06-18 · 3.2y away
DLBCL
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03534574 | NDA/BLA | DLBCL | Terminated | 1076 | Safety |
| NCT05465552 | NDA/BLA | DLBCL | Active | 809 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| HAL-1232 | Halozyme | Approved | C5 |